Compare VTMX & IRTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | VTMX | IRTC |
|---|---|---|
| Founded | 1998 | 2006 |
| Country | Mexico | United States |
| Employees | N/A | N/A |
| Industry | | Medical/Dental Instruments |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.1B | 3.7B |
| IPO Year | 2023 | 2016 |
| Metric | VTMX | IRTC |
|---|---|---|
| Price | $36.31 | $121.26 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 4 | 16 |
| Target Price | $37.40 | ★ $171.33 |
| AVG Volume (30 Days) | 50.6K | ★ 420.3K |
| Earning Date | 10-22-2026 | 11-05-2026 |
| Dividend Yield | ★ 2.30% | N/A |
| EPS Growth | N/A | ★ 61.71 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $747,138,000.00 |
| Revenue This Year | $13.75 | $19.40 |
| Revenue Next Year | $11.48 | $16.65 |
| P/E Ratio | $47.91 | ★ N/A |
| Revenue Growth | N/A | ★ 26.24 |
| 52 Week Low | $28.83 | $100.70 |
| 52 Week High | $37.41 | $210.01 |
| Indicator | VTMX | IRTC |
|---|---|---|
| Relative Strength Index (RSI) | 67.20 | 66.23 |
| Support Level | $33.36 | $119.48 |
| Resistance Level | $36.78 | $125.38 |
| Average True Range (ATR) | 0.84 | 3.94 |
| MACD | 0.29 | 1.82 |
| Stochastic Oscillator | 85.00 | 92.89 |
Corporacion Inmobiliaria Vesta SAB de CV is an internally managed real estate company that owns, manages, develops, and leases industrial properties in Mexico. The Company's primary business is the acquisition, development, and management of industrial and distribution center real estate. The company designs and constructs park-to-suit projects across various industries; undertakes build-to-suit projects; and provides site selection, design and engineering, and sale and leaseback services. The primary source of revenue is the rental income received from customers under operating leases. It serves aerospace, automotive, food and beverage, logistics, medical devices, plastics, and other industries.
iRhythm Holdings Inc is a digital healthcare company that creates trusted solutions that detect, predict, and prevent disease. Its principal business is the design, development, and commercialization of device-based technology to provide ambulatory cardiac monitoring services that it believes allow clinicians to diagnose certain arrhythmias quicker and with greater efficiency than other services that rely on traditional technology. Each Zio System combines an FDA-cleared and CE-marked, wire-free, patch-based, 14-day wearable biosensor that continuously records electrocardiogram (ECG) data with a proprietary, FDA-cleared, CE-marked cloud-based data analytic software to help physicians monitor patients and diagnose arrhythmias.